A detailed history of Sherbrooke Park Advisers LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 29,707 shares of RGNX stock, worth $220,128. This represents 0.07% of its overall portfolio holdings.

Number of Shares
29,707
Previous 15,857 87.34%
Holding current value
$220,128
Previous $186 Million 67.97%
% of portfolio
0.07%
Previous 0.03%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.49 - $14.39 $145,286 - $199,301
13,850 Added 87.34%
29,707 $312 Million
Q2 2024

Aug 14, 2024

BUY
$11.51 - $21.53 $182,514 - $341,401
15,857 New
15,857 $186 Million

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $320M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.